Cell-level experiments suggested exendin (Ex)-4, a GLP-1RA, attenuated prostate cancer growth through the inhibition of extracellular signal–regulated kinase (ERK)-mitogen-activated protein kinase (MAPK) activation (26), which may be responsible for this result. This evidence concerns the gene WNK2 and prostate cancer.